コンテンツへスキップ
Merck

HPA012016

Sigma-Aldrich

Anti-ERBB4 antibody produced in rabbit

enhanced validation

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution

別名:

Anti-ALS19

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
Human Protein Atlas Number:
NACRES:
NA.41

由来生物

rabbit

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

製品種目

Prestige Antibodies® Powered by Atlas Antibodies

形状

buffered aqueous glycerol solution

化学種の反応性

human

強化検証

orthogonal RNAseq
Learn more about Antibody Enhanced Validation

テクニック

immunohistochemistry: 1:50- 1:200

免疫原配列

LPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRK

UniProtアクセッション番号

輸送温度

wet ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... ERBB4(2066)

詳細

ERBB4 (erb-b2 receptor tyrosine kinase 4) is a tissue-specific, tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) subfamily of receptor tyrosine kinases. It exists in two isoform, which are expressed mainly in the neural tissues such as cerebellum. Its expression also has been found in the kidney and heart. The functional activity of the protein is controlled by the neuregulins (NRG), betacellulin (BTC), and heparin-binding EGF-like growth factor.

免疫原

erbB-4受容体型チロシンプロテインキナーゼ前駆体のPrEST(protein epitope signature tag)抗原リコンビナントタンパク質。

アプリケーション

Prestige抗体®は、Human Proteome Resource(HPR)プロジェクト(www.proteinatlas.org)によって開発・実証されたAtlas抗体です。抗体はすべて、数百の正常組織・疾病組織に対する免疫組織染色試験を行っています。これらの染色画像はHuman Protein Atlas(HPA)サイトで[Image Gallery]リンクをクリックするとご覧いただけます。さらに、ほとんどのPrestige抗体はプロテインアレイおよびウェスタンブロッティングの試験を行っています。試験のプロトコールおよびPrestige抗体、HPAに関する情報はsigma.com/prestigeをご覧ください。

生物化学的/生理学的作用

ERBB4 (erb-b2 receptor tyrosine kinase 4) is involved in milk production and anabolic processes in normal mammary epithelia and cancer by controlling the YAP/Hippo pathway and mevalonate pathways. Its phosphatidyl inositol 3-kinase (PI3-K) binding site interacts with several EGF family members including neuregulins (NRG) for cellular responses related to cell proliferation, invasion, and cell growth suppression. Mutation in the kinase domain of ERBB4 is responsible for the malignant cancer cell growth. ERBB4 identifies oncogenic somatic mutations in high-risk early breast cancer, which proves its prognostic marker quality. Mutation in the gene also causes a neurological disorder, amyotrophic lateral sclerosis (ALS).

特徴および利点

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

関連事項

Corresponding Antigen APREST70281

物理的形状

PBS溶液(pH 7.2, 40%グリセロールおよび0.02%アジ化ナトリウム含有)。

法的情報

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our 製品選択ツール.

保管分類コード

10 - Combustible liquids

WGK

WGK 1

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

HPA012016-100UL:
HPA012016-25UL:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Guodong Han et al.
Journal of cellular biochemistry (2019-02-13)
microRNAs are involved in the control of cell growth and apoptosis; they also play an essential role in resistance towards trastuzumab, in breast cancer. The objective of this study was to identify differentially expressed microRNA(s) and explore its therapeutic role
Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells.
Wali VB, Haskins JW, Gilmore-Hebert M, et al.
Molecular Cancer Research, 12(8), 1140-1155 (2014)
Kari J Kurppa et al.
PloS one, 9(7), e102388-e102388 (2014-07-19)
A number of genetic variants have been linked to increased risk of breast cancer. Little is, however, known about the prognostic significance of hereditary factors. Here, we investigated the frequency and prognostic significance of two ERBB4 promoter region variants, -782G>T
Yuji Takahashi et al.
American journal of human genetics, 93(5), 900-905 (2013-10-15)
Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder characterized by the degeneration of motor neurons and typically results in death within 3-5 years from onset. Familial ALS (FALS) comprises 5%-10% of ALS cases, and the identification of genes associated
Kaori Nakatani et al.
Molecular cancer therapeutics, 18(1), 112-126 (2018-10-17)
The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs (rociletinib and osimertinib). We previously reported heterogeneous afatinib-resistant mechanisms

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)